Last reviewed · How we verify
Eltrombopag oral tablets
Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes.
Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes. Used for Chronic immune thrombocytopenia (ITP), Thrombocytopenia in patients with chronic hepatitis C, Aplastic anemia.
At a glance
| Generic name | Eltrombopag oral tablets |
|---|---|
| Also known as | SB-497115-GR oral tablets |
| Sponsor | GlaxoSmithKline |
| Drug class | Thrombopoietin receptor agonist |
| Target | MPL (thrombopoietin receptor) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Eltrombopag binds to the thrombopoietin receptor (MPL) on megakaryocyte progenitor cells in the bone marrow, mimicking the action of endogenous TPO and promoting megakaryocyte proliferation and differentiation. This leads to increased platelet production, thereby raising platelet counts in patients with thrombocytopenia. The drug is a small-molecule, non-peptide TPO receptor agonist that works through a distinct mechanism from other TPO mimetics.
Approved indications
- Chronic immune thrombocytopenia (ITP)
- Thrombocytopenia in patients with chronic hepatitis C
- Aplastic anemia
Common side effects
- Headache
- Nausea
- Diarrhea
- Abdominal pain
- Thrombotic events
- Hepatotoxicity
Key clinical trials
- Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence (PHASE2)
- A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids (PHASE3)
- Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia (PHASE2)
- The Use of Eltrombopag Post HSCT in BMFD (PHASE2, PHASE3)
- Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag (NA)
- Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA) (PHASE2, PHASE3)
- A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP (PHASE2)
- A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eltrombopag oral tablets CI brief — competitive landscape report
- Eltrombopag oral tablets updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI